Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge. And pharma isn’t treating it like one yet.

Swiss pharma giant Novartis is to pay up to $3bn to Synnovation Therapeutics to acquire a promising breast-cancer treatment that has shown to reduce the unwanted side effects of available medicines.

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer ; The lead ...

A homeowner says a housing development is causing flooding and problems with accessing garages.

The truth and law about personal development. This will open your eyes.

Novartis AG agreed to buy an experimental breast cancer drug from Synnovation Therapeutics for as much as $3 billion in a push to bolster its oncology pipeline.

... Read more ...

Trump reveals chief of staff Susie Wiles has breast cancer - First female chief of staff will remain on the job while being ...

Signature sandwiches remain central to both chains’ menus.

After my house jobs, I did a year in oncology with the late Sir Kenneth Calman, who trained initially as a surgeon and ...

A Colorado State University graduate student is leading a biotechnology startup that could change how breast cancer survivors rebuild tissue after surgery, using advanced 3D printing and regenerative ...

Novartis has agreed to acquire SNV4818 from Synnovation Therapeutics, a next-generation PI3Kα inhibitor designed to selectively target mutations in HR+/HER2- breast cancer. The therapy, currently in ...